Frontiers in Immunology · 2023 · 13 citations · 19 references
Veterinary MedicineImmunologyInfectious DiseasesAdaptive ImmunityImmunology Of Infectious DiseasesVaccinologyAdaptive Immune ResponsesB Cell BiologyB-cell ResponsesHumoral ImmunityImmune Response To VaccinationImmune Responses To InfectionAntibodiesB Cell Response To VaccinationB-cell Immune EscapeNeutralizing Antibody ResponsesSars-cov-2 InfectionT-cell Immune ResponsesVaccine-induced Antibody ResponsesVaccine-induced T-cell Responses
Since early 2022, various Omicron variants have dominated the SARS-CoV-2 pandemic in most countries. All Omicron variants are B-cell immune escape variants, and antibodies induced by first-generation COVID-19 vaccines or by infection with earlier SARS-CoV-2 variants largely fail to protect individuals from Omicron infection. In the present study, we investigated the effect of Omicron infections in triple-vaccinated and in antigen-naive individuals. We show that Omicron breakthrough infections occurring 2-3.5 months after the third vaccination restore B-cell and T-cell immune responses to levels similar to or higher than those measured 14 days after the third vaccination, including the induction of Omicron-neutralizing antibodies. Antibody responses in breakthrough infection derived mostly from cross-reacting B cells, initially induced by vaccination, whereas Omicron infections in antigen-naive individuals primarily generated B cells binding to the Omicron but not the Wuhan spike protein. Although antigen-naive individuals mounted considerable T-cell responses after infection, B-cell responses were low, and neutralizing antibodies were frequently below the limit of detection. In summary, the detection of Omicron-associated B-cell responses in primed and in antigen-naive individuals supports the application of Omicron-adapted COVID-19 vaccines, but calls into question their suitability if they also contain/encode antigens of the original Wuhan virus.
19
David Hillus, Tatjana Schwarz, Pinkus Tober‐Lau et al. · The Lancet Respiratory Medicine · 2021 · 355 citations · Full text
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Tina Schmidt, Verena Klemis, David Schub et al. · Nature Medicine · 2021 · 344 citations · Full text